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TRANSFORMING GROWTH FACTOR-13
TGF-/3: Regulation of extracellular matrix
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Extracellular matrix (ECM) is an important determinant of
cellular behavior, regulating cellular adhesion, cellular migra-
tion, cellular proliferation, and cellular differentiation, Increas-
ingly, it has become appreciated that certain of these actions of
ECM derive from its ability to sequester and modulate the
activity of specific growth factors [1]. Of all of the growth
factors, none has been found to have the diversity of effects on
ECM ascribed to transforming growth factor-/3 (TGF-/3). This
peptide plays a critical role not only in synthesis and degrada-
tion of ECM but also in response of cells to ECM mediated
through integrin receptors; moreover, specific components of
the ECM, in turn, can both deliver TGF-/3 and regulate its
activity [reviewed in 2—41.
Five distinct isoforms of TGF-/3 have now been described,
and three of these, called TGF-/3s 1, 2, and 3, are found in all
mammalian species [4]. The gene for each isoform is located on
a different chromosome, and has a distinct 5' flanking sequence
regulating its expression; however, the biological activities of
the mature, activated peptides, which are 60 to 80% homolo-
gous in terms of amino acid sequence, are most often similar to
each other. Thus, it is expected that each of the isoforms would
have similar activities in control of ECM, even though the
original observations in this regard were based principally on
the actions of TGF-/3l (the first member of the family to be
characterized and the most abundant isoform in platelets, which
are often used as a source of the natural peptide). Moreover, the
ability of most cells to both produce and respond to the TGF-/3s
suggests that this activity of TGF-/3 applies to a broad range of
target cells including hematopoietic cells, epithelial cells, and
mesenchymal cells. In this brief overview, we will discuss the
various levels of reciprocal control of ECM and TGF-f3 and
present data linking the actions of TGF-/3 with regulation of
ECM in embryogenesis, in tissue repair, and in a variety of
chronic inflammatory diseases accompanied by fibrosis.
Effects of TGF-J3 on synthesis and degradation of matrix
proteins and expression of integrin receptors
The ability of TGF-/3 to control synthesis of collagen and
fibronectin, first described almost five years ago, has been
shown to be paradigmatic for its action on a wide variety of
proteins found in ECM including types I, II, III, IV, and V
collagen, thrombospondin, osteopontin, tenascin, elastin, hy-
aluronic acid, osteonectin/SPARC, as well as chondroitin!
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dermatan sulfate proteoglycans such as biglycan and decorin
[reviewed in 31. Mechanistically, TGF-/3 has been found to
increase mRNA levels for most of the matrix proteins in which
this has been examined and to result in increased secretion of
the protein. These direct effects of TGF-/3 on synthesis of ECM
components are complemented by its ability to interfere with
proteolytic degradation of matrix proteins. This occurs at two
levels: TGF-/3 reduces synthesis and secretion of several dif-
ferent proteases that act on ECM and increases synthesis of
specific inhibitors of those proteases. As specific examples,
TGF-j3 decreases synthesis of two common proteases, collage-
nase and plasminogen activator, and increases synthesis of
inhibitors of these enzymes, tissue inhibitor of metalloprotein-
ases and plasminogen activator inhibitor. To the extent that it
has been studied, the effects of TGF-/3 on synthesis of both of
these classes of enzymes are also mediated at the level of
increased mRNA encoding these proteins. This ability of
TGF-13 to decrease proteolysis of ECM both augments and
stabilizes its effects on matrix protein synthesis.
The interaction of cells with components of the ECM and in
some cases with other cells is controlled by specific cell-surface
receptors called integrins [5]. These receptors constitute a
family of glycoproteins that both bind ECM components and
link with cytoskeletal elements on the cytoplasmic side. Heino
and Massagué have demonstrated that TGF-/3 increases both
the level of receptor mRNA and the rate of receptor subunit
processing by cells. The several subsets of the a/3l and a/33
integrins, which mediate binding of cells to collagen, fibronec-
tin, and vitronectin are all upregulated by TGF-/3. Moreover,
selective regulation of different a and /3 subunits in different cell
types suggests that TGF-/3 might control cell migration and
differentiation not only through regulation of the composition of
ECM, but also by specifically modulating the ability of the cell
to adhere to different components of the ECM [6].
Role of extracellular matrix in modulating the activity
of TGF-fJ
TGF-/3 is released from platelets and secreted from cells in a
biologically inactive, latent form consisting of a non-covalent
complex of the mature TGF-/3 dimer and another homodimer
consisting of the portion of the TGF-/3 precursor remaining after
cleavage of the N-terminal signal peptide and the C-terminal
mature TGF-/3 peptide [7]. Before it can bind to its receptor,
TGF-/3 must first be dissociated from this complex by a process
referred to as 'activation". Recently, it has been found that
"active" TGF-/3 can again be inactivated by binding to a variety
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of proteins including a2macroglobulin [8] and a-fetoprotein [9],
several matrix components such as type IV collagen [10], and
two proteoglycans, betaglycan [11] and decorin [12].
The binding of TGF-/3 to the core protein of the two proteo-
glycans deserves special mention in terms of its ability to
regulate the bioavailability of TGF-f3 [13]. Betaglycan is a large
polymorphic chondroitin sulfate and/or heparan sulfate proteo-
glycan which binds TGF-p with high affinity [11]; it is found in
both soluble and membrane-anchored forms (formally called
the type III TGF-f3 receptor). The soluble form can be released
by cultured cells and is found in both serum and ECM; the
membrane-anchored form may serve to sequester TGF-/3 on the
cell surface or to present the peptide to its receptor. Decorin is
an abundant small chondroitin sulfate/dermatan sulphate pro-
teoglycan which is a member of a family of leucine-rich proteins
and associates with type I collagen fibrils in tissues. It too has
now been shown to bind TGF-/3 to its core protein with high
affinity, and in doing so neutralizes its activity [12]. Moreover,
since TGF-/3 also induces the synthesis of decorin, binding to
decorin has been suggested to constitute a negative feedback
loop regulating TGF-/3 activity. This was recently demonstrated
in Chinese hamster ovary cells overexpressing decorin in which
it could be shown that the inhibitory effect of the expressed
decorin on the growth of the cells was a function of its ability to
bind and inactivate TGF-/3, which is an autocrine peptide
stimulating the growth of these cells [12].
The avid binding of TGF-$ to these proteoglycans suggests
that they may play roles in the retention, delivery, or clearance
of active TGF-/3. Thus, the binding of TGF-/3 to decorin, which
is an abundant component of ECM might, in some cases, be the
basis of the immunohistochemical localization of TGF-f3 to
ECM; moreover, the ability of decorin to inactivate TGF-/3 has
led to attempts to utilize decorin to inactivate TGF-/3 in
situations where its aberrant expression can result in excessive
fibrosis, as in experimental mesangial glomerulonephritis (see
article by W. Border, this issue).
Another example of the ability of TGF-/3 to bind to ECM is
found in a reconstituted basement preparation called "Matri-
gel". This preparation is available commercially and is often
used experimentally to mimic natural basement membrane.
Recent experiments have demonstrated that Matrigel contains a
variety of bound growth factors including insulin-like growth
factor-I, basic fibroblast growth factor, platelet-derived growth
factor, epidermal growth factor, and TGF-p [14]. Importantly,
Matrigel, unlike decorin, was able to deliver bioactive TGF-13 to
cells. Thus, the number of interconnecting canalicular cell
processes formed by osteoblastic-like MC3T3-EI cells grown
on Matrigel was inhibited by exogenous TGF-j3, but stimulated
by the addition of anti-TGF-f31 neutralizing antibodies [14]. The
reversible binding of bioactive TGF-/3 to Matrigel is similar to
previous observations regarding the binding of TGF-/3 to
a2macroglobulin, where it had been shown that the complex of
TGF-/3 and a2macroglobulin could effectively neutralize the
activity of TGF-/3 in short-term assays, such as receptor bind-
ing, but could release active TGF-/3 to cells in longer term in
vitro assays [8]. Collectively, these data suggest that matrix
proteins may be able to modulate the activity of TGF-/3, in
certain cases possibly sequestering the peptide in specific
association with the ECM to make it available to cells at
appropriate times,
Evidence that TGF-j3 regulates extracellular matrix in vivo
While most of the studies demonstrating effects of TGF-f3 on
synthesis and degradation of matrix proteins have been carried
out in vitro, there is now strong evidence from studies of the
role of TGF-/3 in embryogenesis, in tissue repair, and in fibrotic
diseases that similar mechanisms hold in vivo.
Immunohistochemical studies of the expression of TGF-/31
and type I and III collagens, fibronectin, and proteoglycans
during branching morphogenesis in the developing mouse lung
demonstrate co-localization of TGF-/31 and these matrix pro-
teins in mesenchymal cells surrounding bronchiolar and alveo-
lar ducts and in clefts of branching ducts [15]. Similar co-
localization of TGF-/31 and ECM components has been
reported in branching morphogenesis of the murine mammary
gland and in the cushion tissue of developing heart valves.
In tissue repair, collagen is known to be responsible for the
tensile strength of the healing wound, while fibronectin forms a
scaffold to which cells migrating into the wounded area can
attach. Many studies now demonstrate that exogenous TGF-f3
increases accumulation of matrix proteins in the wound bed,
resulting ultimately in increased tensile strength of incisional
wounds and the rate of healing of ulcer wounds [16]. Moreover,
subcutaneous injection of TGF-13 into newborn mice induces
formation of a localized granulation tissue, and stimulates
elaboration of connective tissue and collagen synthesis [2].
Demonstrating a critical role of endogenous TGF-/3 in the
matrix deposition and scarring which characterize healing of an
incisional wound, is the recent observation that injection of
anti-TGF-/3 antibodies at the time of wounding results in a
marked diminution of the extent of matrix protein deposition
and a reduction in the formation of scar tissue as assessed by
the organization of the collagen fibrils in the wound bed [17].
Similar data have recently been reported in a study of healing of
a penetrating injury of the central nervous system, where it has
been shown that continuous infusion of anti-TGF- antibodies
into the wound markedly reduced the extent of the fibrotic scar
[181.
It follows from the above that sustained, aberrant expression
of TGF-f3, would result in pathological accumulation of matrix.
Indeed, there is now unequivocal data implicating TGF-j3 in the
pathogenesis of several chronic inflammatory diseases includ-
ing pulmonary fibrosis [19], glomerulonephritis [20], and prolif-
erative vitreoretinopathy [21]. Each of these diseases is char-
acterized by increased expression of TGF-13 protein and
excessive accumulation of ECM. Moreover, in experimental
models of pulmonary fibrosis (J. McDonald, personal commu-
nication) and glomerulonephritis [20; see also article by W.
Border, this issue] it has been shown that systemic administra-
tion of anti-TGF-/3 antibodies attenuated the histologic mani-
festations of the disease. Conversely, a fibrotic condition of the
vitreous resulting in traction retinal detachment and mimicking
proliferative vitreoretinopathy could be induced by injection of
TGF-/3 and fibronectin into the vitreous cavity of rabbit eyes
[21].
Putative role of TGF-/3 in kidney disease
Effects of TGF-/3 are not limited to control of ECM, but
encompass all aspects of cellular behavior including migration,
proliferation, and differentiation. Moreover, effects of TGF-/3
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are dependent on context, that is, the specific cellular architec-
ture including both cell-cell and cell-matrix interactions. In the
kidney, TGF-/3s are present in both the cortex and medulla, and
they have been shown to inhibit DNA synthesis and attenuate
the effects of many mitogenic peptides on isolated renal glomer-
ular endothelial, epithelial, and mesangial cells in vitro [221.
Moreover, recent in vivo data demonstrate that expression of
the TGF-/3s in renal cells can be modulated in response to stress
or disease. Thus, expression of the type 2 isoform of TGF-/3 is
specifically enhanced in extraglomerular mesangial cells and
smooth muscle cells of the glomerular arteriole following water
deprivation; expression of TGF-f3s 1 and 3 was localized to
renal tubular epithelial cells and remained unchanged [23].
Finally, correlating with the ability of TGF-p to stimulate
matrix protein synthesis of both glomerular epithelial and
mesangial cells in vitro [22], is the observation that the type 1
isoform of TGF-3 plays a critical role in glomerulonephritis
[20]. Experiments in an animal model system suggest that
anti-TGF-/3 therapy may have application clinically to amelio-
rate the pathological manifestations of the disease [20].
Reprint requests to Dr. Anita B. Roberts, Laboratory of Chemopre-
vention, NIH/Nd, Building 41, Room C629, Bethesda, Maryland
20892, USA.
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